Society France protests: Latest developments
Hundreds of protests were held in France Saturday as nationwide anger grows over the cost of living, with security forces massing to prevent a repeat of...
Homepage
Connect with the world In real time
Trusted, factual and independent reporting from 1,840 journalists worldwide
Top stories
Make your coverage stand out with AFP services
From breaking news to multimedia production and global distribution, access trusted content and services at scale
AFP behind the scenes
Get behind the scenes of AFP journalism with immersive on-the-ground reporting, and follow the Agency’s key announcements.
Inspiring partnerships worldwide
Working with partners across investigative journalism and innovation
Content partnerships
Editorial content agreements and syndication partnerships supporting newsrooms worldwide.
See more
European Projects
AFP is currently a partner in 15 European projects focused on fact-checking, innovation, media collaboration, data journalism, and the development of content-exchange platforms.
Discover all our projects
Philanthropic Partnerships
To help shape a better future for society and the planet, AFP is partnering with philanthropic organisations to provide in-depth reporting on the most vital issues facing humanity.
Learn more
Visual content partners worldwide
Access industry-leading photo agencies and picture libraries from across the globe.
Learn more
Press releases distribution
Partners distributing official statements and corporate announcements through AFP channels.
See more
Products & Services
Technology, media and service companies working alongside AFP to deliver trusted information.
See more
Institutional and corporate communication
Distributed by MediaConnect (AFP group)
-
Press release from Gustave Roussy-Saturday 24 October 2026. Dr Joana Ribeiro, medical oncologist in the Drug Development Department at Gustave Roussy, will present the results of the POP-DURVA clinical trial at the ESMO...
-
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising anti...
-
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight povetacicept’s...
Browse 25,000+ distributed press releases
Discover official statements, corporate announcements and distributed content from organisations worldwide.
Bring trusted information to your audiences
Get in touch to find out how AFP content, services, and global network can support your newsroom or organisation.
Contact us